// App-Quantinova.ai

178 : Long-term improvements in physical function of disease-modifying anti-rheumatic drug/biologic-experienced and disease-modifying anti-rheumatic drug-naïve psoriatic arthritis subjects treated with apremilast

Researchers

Presenter

  • Philip J Mease

Principal Investigators

  • Alvin F Wells

  • Jurgen Wollenhaupt

  • Stephen Hall

  • Filip Van den Bosch

  • Eric Lespessailles

  • Dianne Nguyen

  • Lichen Teng

  • Christopher J Edwards

Medical Centers

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Rheumatology, Rheumatology and Immunotherapy Center, Franklin, WI, USA

  • Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, GERMANY

  • Rheumatology, Monash University, CabriniHealth, Melbourne, AUSTRALIA

  • Rheumatology, UZ Gent, Gent, BELGIUM

  • Rheumatology, University of Orléans, Orleans, FRANCE

  • Medical Affairs, Celgene Corporation - USA, Summit, NJ, USA

  • Biostatistics, Celgene Corporation, Summit, NJ, USA

  • Rheumatology, University of Southampton NHS FT, Southampton, UNITED KINGDOM

Locations

  • United States

  • Germany

  • Australia

  • Belgium

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved